A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy

C Loef, Corrina de Ridder, Suzanne Reneman, Marije Crezee, A Dalgleish, SM Todryk, C.H. Bangma, Robert Kraaij

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)


A panel of cytokine-secreting RM-9 prostate cancer cells were tested as whole cell vaccines to determine their capacity to evoke an anti-prostate cancer immune response. In our model, vaccines secreting mGM-CSF or mIL-7 resulted in the highest increase in circulating T lymphocytes after vaccination, prolonged survival and, in a proportion of animals, tumor-free survival. Anti-tumor effects were more evident after a subcutaneous RM-9 challenge than after an intraprostatic challenge. However, when the RM-9/mGM-CSF cell line was used as intraprostatic tumor challenge, protection after RM-9/mIL-7 vaccination was restored.
Original languageUndefined/Unknown
Pages (from-to)373-381
Number of pages9
JournalCancer Immunology Immunotherapy
Issue number3
Publication statusPublished - 2009

Cite this